More on VSTM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $6.00 |
|
|||
| Open | $6.01 | ||||
| 52 Wk High | $2.43 | ||||
| 52 Wk Low | $1.05 | ||||
| Day High | $6.11 | ||||
| Day Low | $5.75 | ||||
| P/E | N/A | ||||
| EPS | $-1.79 | ||||
| Volume | 1,342,918 | ||||
- Verastem doses first patient in lung cancer trial for VS-7375
- Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
- Form SCHEDULE 13G/A Verastem, Inc. Filed by: Polar Capital Holdings Plc
- Verastem (VSTM) PT Lowered to $14 at RBC Capital
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Form 144 Verastem, Inc. Filed by: Gagnon Robert E.
- Form 4 Verastem, Inc. For: Jun 22 Filed by: Paterson Dan
- Form 4 Verastem, Inc. For: Jun 22 Filed by: Calkins Daniel
- RBC Capital on Verastem (VSTM): 'We think shares are undervalued'
- H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)
Entities mentioned with VSTM
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Pre Market Movers | View Related Stories »
- Show More...
